Introduction
Epilepsy is a common neurological disorder that affects about 1% of the world's population (Sander, 2003) . Epilepsy syndromes are usually either symptomatic and due to a known brain injury or idiopathic and not due to brain injury. Idiopathic genetic epilepsy syndromes (IGES) comprise~30% of all cases and can vary in severity from the mild childhood absence epilepsy syndrome to the severe Dravet syndrome (Reid et al., 2009; Steinlein, 2004) . While many IGES are benign, Dravet syndrome is not. It is associated with myoclonic and generalized tonic-clonic seizures that begin at an early age, frequent episodes of status epilepticus and progressive intellectual decline, and it is resistant to a wide range of antiepileptic drugs. About one half of Dravet syndrome-associated mutations are nonsense mutations in genes such as voltage-gated sodium channels that create premature translation-termination codons (PTCs), and thus, truncated subunit proteins (De Jonghe, 2011) . Although rare, nonsense mutations in GABA A receptor subunit genes have been identified also in Dravet syndrome patients (Harkin et al., 2002) . GABRG2(Q40X) is a nonsense mutation located in GABA A receptor γ2 subunits that has been associated with Dravet syndrome (Kanaumi et al., 2004) .
GABA A receptors are heteropentameric chloride ion channels that mediate the majority of inhibitory neurotransmission in the CNS. The receptor complex is composed of five subunits from nineteen different genes, and the main synaptic receptors are composed of two α subunits, two β subunits and one γ2 subunit. Out of the fifteen GABR epilepsy-associated mutations or variants, seven are in GABRG2, and these mutations have been shown to decrease channel function by altering receptor biogenesis or channel function (Macdonald and Kang, 2009 ). The GABRG2(Q40X) mutation was shown to impair GABA A receptor channel function and to form granules in neurons (Kanaumi et al., 2004) . However, the effects of this mutation on GABA A receptor function are unknown.
Current therapies for the devastating epilepsies produced by truncation mutations are symptomatic and relatively ineffective. One potential treatment would be to rescue the nonsense mutation by 
